EVOK vs. CYCC, ATXI, ALLR, INM, CNSP, APVO, PBLA, CMND, CWBR, and QLGN
Should you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Cyclacel Pharmaceuticals (CYCC), Avenue Therapeutics (ATXI), Allarity Therapeutics (ALLR), InMed Pharmaceuticals (INM), CNS Pharmaceuticals (CNSP), Aptevo Therapeutics (APVO), Panbela Therapeutics (PBLA), Clearmind Medicine (CMND), CohBar (CWBR), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical preparations" industry.
Evoke Pharma (NASDAQ:EVOK) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 11.8% of Evoke Pharma shares are held by insiders. Comparatively, 8.5% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Evoke Pharma has higher revenue and earnings than Cyclacel Pharmaceuticals. Evoke Pharma is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cyclacel Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 950.00%. Given Cyclacel Pharmaceuticals' higher possible upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Evoke Pharma.
Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Evoke Pharma's net margin of -150.43%. Cyclacel Pharmaceuticals' return on equity of -448.19% beat Evoke Pharma's return on equity.
Evoke Pharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
Evoke Pharma received 174 more outperform votes than Cyclacel Pharmaceuticals when rated by MarketBeat users. Likewise, 63.05% of users gave Evoke Pharma an outperform vote while only 49.60% of users gave Cyclacel Pharmaceuticals an outperform vote.
In the previous week, Evoke Pharma had 3 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 7 mentions for Evoke Pharma and 4 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.87 beat Evoke Pharma's score of 0.47 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.
Summary
Cyclacel Pharmaceuticals beats Evoke Pharma on 9 of the 17 factors compared between the two stocks.
Get Evoke Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Evoke Pharma Competitors List
Related Companies and Tools